- Data on investigational, once-daily TMC278, the third antiretroviral compound developed by Tibotec Pharmaceuticals, presented at International AIDS Conference -Contact: Hans Vanavermaete Mobile: +32 (0) 478 44 72 78 Pamela Van Houten Mobile: +1 908-295-7367
